Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4024 studies found for:    Open Studies | "Immune System"
Show Display Options
Rank Status Study
21 Recruiting Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Multiple;   Mycosis Fungoides;   Hodgkin's Lymphoma;   Multiple Myeloma
Intervention: Drug: Dasatinib
22 Recruiting The Immune System's Response to Young Women's Breast Cancer
Conditions: Breast Cancer;   Breast Cancer and Pregnancy
Intervention:
23 Recruiting Immune Profile in Subjects With New Onset Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Procedure: Inguinal lymph node fine needle aspirate biopsy;   Procedure: Inguinal lymph node core biopsy;   Procedure: Peripheral blood collection;   Other: Pre- and post-biopsy questionnaire
24 Recruiting Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Conditions: Immunosuppression;   Periodontal Disease;   Healthy Subjects;   Healthy Volunteer
Intervention:
25 Recruiting Influenza in People With Normal and Weakened Immune Systems
Condition: Influenza
Intervention:
26 Recruiting Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Condition: APECED
Intervention:
27 Recruiting Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD
Condition: Chronic GVHD After HCT for Cancer or Immune Disease
Intervention: Other: Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
28 Recruiting Antibody Production in Immune Disorders
Condition: Immunologic Disease
Intervention:
29 Recruiting Influenza Vaccination and COPD Phenotypes
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Other: Influenza Vaccination
30 Recruiting Characterization of Phenotype and Genotype of Early Onset Enteropathies
Condition: Inflammatory Bowel Disease
Intervention: Other: Biological sampling
31 Recruiting Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer
Condition: Cancer
Intervention: Drug: [18F]F-AraG
32 Recruiting SIBO, Immune Activation, and FGIDs in Children
Conditions: Small Intestinal Bacterial Overgrowth;   Irritable Bowel Syndrome;   Functional Dyspepsia;   Functional Abdominal Pain
Intervention:
33 Recruiting Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Condition: Dementia Alzheimer's Type
Interventions: Drug: Sargramostim GZ402664;   Drug: Placebo;   Drug: Florbetapir F18
34 Recruiting Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies
Conditions: Primary T-cell Immunodeficiency Disorders;   Common Variable Immunodeficiency;   Immune System Diseases;   Autoimmune Lymphoproliferative;   Lymphoproliferative Disorders
Interventions: Drug: Immunosuppression Only Conditioning;   Drug: Reduced Intensity Conditioning;   Drug: Myeloablative Conditioning;   Drug: GVHD Prophylaxis;   Procedure: Allo BMT
35 Recruiting Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease
Condition: Graft -Versus-host-disease
Intervention: Biological: Mesenchymal stromal cells
36 Recruiting Auto-immune Diseases and Quality of Life
Conditions: Systemic Auto-immune Diseases;   Quality of Life
Intervention: Other: completion of the quality of life questionnaire
37 Recruiting Vaccination Responses in Young and Older Adults
Conditions: Individuality;   Healthy;   Asthma;   Immune System and Related Disorders
Intervention: Biological: Pneumococcal Vaccination
38 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
39 Recruiting Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis;   Autoimmune Diseases;   Immune System Diseases;   Nervous System Diseases;   Autoimmune Diseases of the Nervous System
Intervention: Drug: BAF312
40 Recruiting Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Condition: Graft vs Host Disease
Interventions: Biological: Begelomab;   Biological: Conventional Second-line Treatment

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.